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Massachusetts Department of Public Health 
Minutes of the Drug Formulary Commission 
Meeting of Thursday, May 5, 2016 
Henry I. Bowditch Public Health Council Room, 2nd Floor 
250 Washington Street, Boston, MA 
 
 
Date of Meeting:  Thursday, May 5, 2016 
Beginning Time:  2:01 PM 
Ending Time:  4:21 PM 
 
Advisory Council Members Present: The following thirteen (13) appointed members of the 
Drug Formulary Commission attended on May 5, 2016, establishing the required simple majority 
quorum (9) pursuant to Massachusetts Open Meeting Law (OML): DPH Interim Director Bureau 
Health Care Safety and Quality Eric Sheehan (Chair); Dr. Douglas Brandoff; Ray Campbell; Dr. 
Daniel Carr; Dr. Joanne Doyle-Petrongolo; Dr. Ken Freedman; Dr. Paul Jeffrey; Dr. Virginia 
Lemay; Cindy Steinberg; Dr. Jeffrey Supko; Dr. Theoharis Theoharides; Ms. Tammy Thomas 
and Dr. Alexander Walker. 
 
 
1. Welcome and Introductions 
 
Department of Public Health (DPH) Bureau of Health Care Safety and Quality Interim Director 
Chair Eric Sheehan called the meeting to order at 2:01PM and provided brief introductory 
remarks.  
 
Mr. Sheehan reminded the attendees that this is a recorded, public hearing, and confirmed that no 
one in audience was recording. 
 
Mr. Sheehan summarized the April 7, 2016 meeting.  He noted that the Commission at its last 
meeting began crosswalking the Abuse Deterrent Property (ADP) drug products it approved as 
potential substitutes with the drug products it determined have a Heightened Public Health Risk.   
 
Data was presented on Embeda and several drug products for which it may be substituted, based 
on statutory criteria, and the definition approved for Chemically Equivalent Substitution and the 
form approved to determine the strength of evidence showing ADP Efficacy. 
 
However, the Commission found that more data was needed to determine if the pairings fit the 
approved definition. In particular, the Commission determined that more data was needed to 
determine if the potential substitute produces a comparable biologic effect as the drug for which 
it was being considered as a substitute. This data will be presented today. 
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Mr. Sheehan called for approval of the minutes from the April 7, 2016 meeting. 
 
 One typo was corrected by Dr. Carr. Dr. Carr also suggested edits to a statement by Dr. 
Jeffrey on page 5.  
 Motion to approve: Ms. Steinberg 
 Second: Dr. Carr 
 All in favor: 8 in favor; 0 opposed; 3 abstention.  
Dr. Freedman, Dr. Lemay and Ms. Thomas abstained as they were not present at the 
April 7
th
 meeting. 
 
2. Crosswalk 
 
Next, Mr. Sheehan reviewed the drugs on the 28 Heightened Public Health Risk drugs on List A 
and the five potential formulary substitutes on List B.  Mr. Sheehan explained that the goal of the 
Crosswalk in Component 3 is to determine whether a drug product on List B should be a 
substitute for one or more drug products on List A.  The Commission members were provided 
with complete lists, with accompanying cost and utilization data. 
 
Mr. Sheehan stated that Section 13 of Chapter 17 of the General Laws guides the Commission’s 
work in Component 3 by offering four criteria by which we determine that a drug is a chemically 
equivalent substitution.  In addition to the definition of the term “chemically equivalent 
substitution” itself, the Commission must consider accessibility, cost, drug effectiveness, and 
ADP efficacy.   
 
As the Commission evaluates each pairing based on these criteria, it is important to note that the 
totality of the factors should determine whether a List B drug product should substitute for a List 
A products.  Factors should be considered in order for the Commission to meet its goal of finding 
safer alternatives for Heightened Public Health Risk Drugs.  This is especially true of cost.  
 
At the April 7
th
 meeting, the members had several questions about the methodology and the 
completeness and relevance of the cost impact data. Karen Stevens, who attended the meeting on 
behalf of Tyson Thompson from UMass, provided an overview of the cost impact data. 
 
Dr. Carr remarked on the cost methodology and noted that just because a drug is less expensive 
does not mean it should be prescribed over a more expensive drug. 
 
Next, Jonathan Mundy introduced four pieces of pharmacokinetic data as requested by the 
members: Peak Concentration; Time to Peak Concentration; Elimination Half-Life; and Area 
Under the Curve (AUC).  There was discussion on this data. 
 Dr. Supko noted that AUC is a measure of absorption – comparable effect. 
 Dr. Carr clarified that each drug was studied individually, and that no data from one 
informed the other. He noted, however, that this data gives a good ball park comparison. 
 Dr. Steinberg asked about the perceived variation in the Embeda and Avinza data. 
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 Dr. Supko explained that different doses of the two drugs were studied. 
 Ms. Steinberg asked for clarification on peak concentration and how quickly an 
individual may reach the amount of available drug. 
 Dr. Theoharides advised members to keep in mind that the AUC similar for all but 
Avinza®.  
 
Mr. Mundy introduced the potential pairing of Embeda, one of the List B drug products, and 
Morphine extended-release 24 hour capsule, a List A drug product.  Mr. Mundy described the 
following information for each drug product: active ingredient; strength; dosage form; route of 
administration; dosing schedule; cost per unit; units dispensed in 2015; the approximate cost paid 
for these units; and the ADP efficacy category.   
 
Following this review, the floor was opened for discussion. Commission members offered 
the following observations, comments, suggestions and recommendations: 
 
 Dr. Carr noted that there may be drugs that aren’t considered chemically equivalent under the 
Commission’s purview or definition that could be flagged.  There are factors that should be 
considered when looking at each drug.  Mr. Sheehan stated that DPH could provide guidance 
once the Formulary is in place.   
 Ms. Steinberg asked if the 178 patients noted on Slide 12 represent 100% conversion.  Ms. 
Stevens replied that it does. 
 Dr. Jeffrey asked about the difference in the drugs listed on slide 11 and those on the 
following slides.  Ms. Stevens responded by explaining that each slide is comparing 
Embeda® to: 
o Slide 12 is generic Avinza®. 
o Slide 13 is Kadian®. 
o Slide 14 is generic Kadian®. 
o Slide 15 is MS Contin®. 
o Slide 16 is generic MS Contin®.    
 Dr. Brandoff stated that he appreciated the additional data but emphasized that the ultimate 
caveat in working with individual patients is that you have to monitor the patient.  The data 
shows that some patients will have different experiences which need to be monitored and 
adjusted, which is independent of whether or not the drug has ADPs.  The data shows that the 
ultimate destination for patients is reasonably similar. 
 Dr. Freedman asked for clarification on the cost of substitution on slide 12.  Ms. Stevens 
explained that it included converting patients that were receiving generic Avinza®, or the 
morphine extended-release 24 hour capsule, to Embeda®. 
 
Next, Mr. Mundy introduced the potential pairing of Embeda® and Kadian®.  Mr. Mundy 
described the following information for each drug product: active ingredient; strength; dosage 
form; route of administration; dosing schedule; cost per unit; units dispensed in 2015; the 
approximate cost paid for these units; and the ADP efficacy category.   
 
Following this review, the floor was opened for discussion. Ms. Steinberg asked why this 
substitution may result in cost avoidance.  Ms. Stevens responded by explaining that this is 
one scenario where Kadian® is more expensive than Embeda®. 
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Mr. Mundy went through the information on the potential pairing of Embeda® and generic 
Kadian®, or the morphine extended-release 12 or 24 hour capsule.  Mr. Mundy described the 
following information for each drug product: active ingredient; strength; dosage form; route of 
administration; dosing schedule; cost per unit; units dispensed in 2015; the approximate cost paid 
for these units; and the ADP efficacy category.  There were no questions or discussion on this 
potential pairing. 
 
Next, Mr. Mundy introduced the potential pairing of Embeda® and MS Contin®.  Mr. Mundy 
described the following information for each drug product: active ingredient; strength; dosage 
form; route of administration; dosing schedule; cost per unit; units dispensed in 2015; the 
approximate cost paid for these units; and the ADP efficacy category.   
 
Following this review, the floor was opened for discussion. Commission members offered 
the following observations, comments, suggestions and recommendations: 
 
 Dr. Supko stated that he believes these are two different products with different 
properties. MS Contin® is faster acting. 
 Dr. Walker asked if there will be another opportunity to compare or substitute a drug with 
ADPs for MS Contin®.  Mr. Sheehan responded saying that it would not happen at this 
time.  Ms. Steinberg stated that there are drugs in the FDA pipeline and we shouldn’t 
substitute unless we are sure. 
 Dr. Carr asked if we would be able to provide guidance to show that the Commission is 
aware of certain factors that should be taken into consideration when prescribing one of 
the drugs that is recommended for substitution. Mr. Sheehan stated that this was possible. 
 
Mr. Mundy introduced the final potential pairing of Embeda® and generic MS Contin®, or the 
morphine extended-release tablet. Mr. Mundy described the following information for each drug 
product: active ingredient; strength; dosage form; route of administration; dosing schedule; cost 
per unit; units dispensed in 2015; the approximate cost paid for these units; and the ADP efficacy 
category.   
 
Following this review, the floor was opened for discussion. Commission members offered 
the following observations, comments, suggestions and recommendations: 
 
 Mr. Campbell asked what the 27,109 patients that were prescribed the generic MS 
Contin®, or the morphine extended-release tablet, in 2015 represented in terms of the 
percentage of total Prescription Monitoring Program (PMP) patients.  Mr. Mundy 
stated that we do not have that information but this is a popular drug.  It has been 
around for a long time and is easy to manipulate and abuse.  It has a high-abuse 
potential. 
 Dr. Walker stated that, in total, over 28,000 were prescribed the five drugs that are 
considered to be substituted by Embeda®.  We are trying to save lives through the 
development of the Formulary.  Dr. Walker expressed that expense of the substitution 
as equivalent to $2 million per life potentially saved by the substitution. If you look at 
the cost, we need to consider if each life is worth the cost of the substitution.  If we 
 5 
 
don’t include this substitution but include the others, we still have a big problem 
because this is the number 1 abused drug.  However, there needs to be a balance 
because they are not comparable. 
 Dr. Brandoff stated that they may not be comparable but asked if they were inferior.  
For the cost of substitution, we need to look at who is paying for it.  If we don’t do 
the substitution, what other costs are being created? Dr. Brandoff urged the members 
not to look at the cost of the substitution in a vacuum, but to consider the cost of 
overdoses and substance use disorder treatment. 
 Dr. Doyle-Petrongolo noted that the Formulary is supposed to be a guideline.  It is 
not written in stone but provides an option.  This doesn’t have to be applicable to 
every person.  The Commission was developed to look at these hard issues. 
 Mr. Sheehan stated that prescribers know their patients.  We are not telling them to 
change prescriptions but giving them a tool for them to use to address patients that 
are at risk of potential abuse. 
 Dr. Freedman indicated that we need to consider that some of the patients that are 
currently prescribed the morphine extended-release tablet may switch to heroin.  We 
need to make Formulary decisions that are in the best interest of the entire population 
and Commonwealth. 
 Dr. Carr stated that this is not as simple as looking at the four pharmacokinetic data.  
There is room to recommend a switch in prescribing if a drug doesn’t work for a 
patient, He noted the fact that this drug accumulates in the system, creating a “steady 
state”.  
 Dr. Jeffrey reminded the members that some people will also become addicted to 
Embeda, but if the Commission does not approve MS Contin and the generic, they will 
have done nothing. 
 Dr. Theoharides asked about the source for the data for the morphine extended-
release tablet. Ms. Stevens indicated that all data is from the FDA’s website. 
 
At this time, Mr. Sheehan asked the members if there were any more comments on each 
potential pairing before considering moving toward a vote on each. 
 
 Dr. Jeffrey indicated that we do not have data on cost effectiveness of ADP drugs 
because they are too new.  This is an area of emerging public policy about the way 
we value lives.  We are reflecting on a greater charge.   
 Dr. Walker asked if the Commission has the opportunity to impact the roll-out of the 
Formulary.  Can we create categories or a tiering system of recommended 
substitutions?  Mr. Sheehan responded by asking if tiered recommendations impact 
the prescriber/patient relationship. 
o Dr. Walker stated that this would help prescribing practices. 
o Dr. Brandoff noted that we need to provide guidance with instructions so 
prescribers are aware of the variables. 
o Dr. Doyle-Petrongolo described the “Beers Criteria” that is used for 
prescribing for the elderly.  It has a tiered system. 
 
Mr. Sheehan called for a break until 3:45 PM.   
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The meeting was called back to order at 3:50 PM. 
 
Mr. Sheehan stated that the voting would begin with the possible substitution of Embeda® 
for the morphine extended-release 24 hour capsule.  Dr. Carr asked what factors should be 
considered when voting.  Mr. Sheehan responded that the totality of all the information 
presented should be considered. 
 
Mr. Sheehan asked if there was a motion to approve Embeda® as a substitute for morphine 
extended-release 24 hour capsule. 
 
 Motion to approve: Dr. Freedman  
 Second: Dr. Jeffrey 
 All in favor: 11 in favor; 1 abstention.  
o Ms. Thomas abstained. 
 Dr. Carr stated that he wants to make sure the Formulary states that the substitutions 
are voluntary.   
 
Mr. Sheehan stated that the next vote would be the possible substitution of Embeda® for 
Kadian®.  Mr. Sheehan asked if there was a motion to approve Embeda® as a substitute for 
Kadian®.   
 
 Motion to approve: Dr. Jeffrey 
 Second: Dr. Theoharides 
 All in favor: 11 in favor; 1 abstention.  
o Ms. Thomas abstained. 
 
Mr. Sheehan stated that the next vote would be the possible substitution of Embeda® for the 
morphine extended-release 12 or 24 hour capsule.  Mr. Sheehan asked if there was a motion 
to approve Embeda® as a substitute for the morphine extended-release 12 or 24 hour 
capsule.    
 
 Motion to approve: Dr. Theoharides 
 Second: Dr. Jeffrey  
 All in favor: 11 in favor; 1 abstention.  
o Ms. Thomas abstained. 
 
Mr. Sheehan stated that the next vote would be the possible substitution of Embeda® for MS 
Contin®.   
 Dr. Supko stated that we know this substitution doesn’t fit the definition.  A 1:1 
substitution doesn’t match.  It may be appropriate under a different definition but it 
doesn’t fit this one. 
 Dr. Theoharides asked if there could be consideration of approving the substitution with 
guidance.  Mr. Sheehan noted that the motion could include the addition of guidance or 
advisory to be included.  It could be the Commission’s way to make sure guidance 
would be included. 
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 Dr. Supko indicated that we need to consider if other products come along through the 
FDA process.  Mr. Sheehan stated that we could regularly update the guidance if 
something in the market changes. That’s why the Commission will continue to meet. 
 Dr. Theoharides noted that some members may feel more comfortable if we determined 
the language for the guidance now.  Mr. Sheehan stated that it wasn’t on the public 
agenda but we can do this at a future meeting. 
 Dr. Supko stated that it is wrong to substitute products that are not bioequivalent.  
Physicians may think that they are comparable but it is misleading.  This substitution 
would not get through the FDA.   
 
Mr. Sheehan asked if there was a motion to approve Embeda® as a substitute for MS 
Contin® with additional guidance.    
 
 Motion to approve: Dr. Walker 
 Second: Dr. Freedman 
 All in favor: 8 in favor; 3 in opposition; 1 abstention.  
o Dr. Jeffrey, Dr. Lemay and Dr. Supko voted in opposition. 
o Ms. Thomas abstained. 
 
Mr. Sheehan stated that the next vote would be the possible substitution of Embeda® for the 
morphine extended-release tablet.  Mr. Sheehan asked if there was a motion to approve 
Embeda® as a substitute for the morphine extended-release tablet with additional guidance.    
 
 Motion to approve: Dr. Walker 
 Second: Dr. Theoharides 
 All in favor: 8 in favor; 3 in opposition; 1 abstention.  
o Dr. Jeffrey, Dr. Lemay and Dr. Supko voted in opposition. 
o Ms. Thomas abstained. 
 
Dr. Walker asked if those that are in opposition to this pairing wanted to voice the reasons 
why they are opposed.  Dr. Supko noted that he already stated his position. 
 
Mr. Sheehan noted that for the next meeting, the Commission will go through a similar 
process for Oxaydo.  We will review several potential pairings and discuss and vote on each 
option.  We will also reconsider the monograph and other data relevant to your previous 
discussion on approval or rejection of Zohydro as a potential Component 3 substitute; and 
may proceed with the crosswalking of Hysingla. 
 
Additionally, Mr. Sheehan indicated that the Commission will address its responsibilities 
under the Opioid Bill that was signed by the Governor in March. In upcoming meetings, the 
Commission will be presented with a potential list of FDA-approved non-opioid pain 
management alternatives with a lesser potential for abuse than Schedule II or III opioids, for 
your approval and publication. 
 
DPH is working to identify additional meeting times in May, June and July.  From the 
information that has been received, it is apparent that we will not have quorum for our next 
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scheduled meeting on May 19.  The Commission is very close to finishing the draft 
Formulary and hope that everyone understands the sense of urgency to getting it done as 
soon as possible. 
 
As part of closing remarks, Mr. Sheehan summarized the votes taken.  The Commission 
voted to: 
 Approve Embeda® as a chemically equivalent substitute for Morphine Extended-
Release, 24-hour capsule. 
 Approve Embeda® as a chemically equivalent substitute for Kadian®. 
 Approve Embeda® as a chemically equivalent substitute for Morphine Extended-
Release, 12 or 24-hour capsule, which is the generic for Kadian. 
 Approve, with additional guidance, Embeda® as a chemically equivalent substitute 
for MS Contin®. 
 Approve, with additional guidance, Embeda® as a chemically equivalent substitute 
for Morphine Extended-Release tablet, which is the generic for MS Contin®. 
 
Having no further business before the Commission, Mr. Sheehan asked for a motion to adjourn.  
 
 Motion: Dr. Jeffrey 
 Second: Dr. Brandoff 
 All in favor: unanimous 
 
The Drug Formulary Commission meeting concluded at 4:21 PM.  
 
Documents Presented to DFC at the May 5, 2016 Meeting 
 
 DFC Minutes from April 7, 2016 
 DFC PowerPoint presentation 
 Cost Information on Short-Acting and Long-Acting Opioids  
 Embeda ADF Efficacy Form 
 Hypothetical Example for Cost Impact Methods    
 
Documents can be found at: 
http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/drug-control/drug-formulary-
commission.html 
 
 
